The BioHub: The Top Voices in Biotech Episode 124 - Jason Ehrlich - CEO & Co-Founder of Ollin Biosciences
6 snips
Feb 26, 2026 Jason Ehrlich, physician-scientist and CEO of Ollin Biosciences, blends clinical insight with biotech leadership. He discusses building a pipeline for serious eye diseases, designing optimized bispecific therapies like OLIN-324 and OLN-102, strategies for efficient clinical development and fundraising, and creating a remote, science-first company culture.
AI Snips
Chapters
Books
Transcript
Episode notes
How A Genentech Fellowship Shaped A Career
- Jason Ehrlich trained as an MD-PhD at Stanford then did an industry fellowship at Genentech that launched his drug development career.
- That fellowship led to 10 years at Genentech/Roche (global head of late-stage ophthalmology) and later CMO at Kodiak, shaping his path to founding Ollin.
Platform Company Strategy For Ophthalmology
- Ollin was founded to survey ophthalmology broadly rather than spin out a single platform, targeting high-impact indications across the field.
- The plan: assemble experienced teams, KOL relationships, and investor partners to acquire and develop optimized assets over a 5+ year horizon.
OLN324 Designed For Potency And Duration
- OLN324 is a small-format VEGF-Ang2 bispecific optimized for potency, size, and high molar dosing to improve retinal penetration and duration versus current anti-VEGF therapies.
- Jason expects head-to-head readout versus Vabysmo early Q1 2026 to test those differentiators clinically.
